BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 23703868)

  • 1. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
    Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
    J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
    Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
    Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
    Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
    Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
    Zhang R; Chen J; Liu D; Wang Y
    Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
    Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
    Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
    Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
    Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
    J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.
    Zhang ZQ; Qiu JF; Luo M; Sun YW; Zhao G; Chen W; Liu H; Wu ZY
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e487-93. PubMed ID: 18070013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
    Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
    Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
    Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
    Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
    Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
    Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
    Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents.
    Kageyama Y; Ikeda H; Watanabe N; Nagamine M; Kusumoto Y; Yashiro M; Satoh Y; Shimosawa T; Shinozaki K; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Yokota H; Koyama T; Ishimaru K; Okamoto Y; Takuwa Y; Koike K; Yatomi Y
    Hepatology; 2012 Oct; 56(4):1427-38. PubMed ID: 22505286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.